Jade Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
JBIO$16.40+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(IN THOUSANDS, EXCEPT SHARE AMOUNTS)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | | | |
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · Shares · Amount · Capital · (Loss) Income · Deficit · Equity | |||||||||||||||||
| Balance at December 31, 2022 | 24,722,974 | | $2 | | $215,110 | | $(466) | | $(87,903) | | $126,743 | ||||||
| Unrealized gain on investments | — | | — | | — | | 703 | | — | | 703 | ||||||
| Stock based compensation | — | | — | | 11,906 | | — | | — | | 11,906 | ||||||
| Issuance of common stock in connection with ATM, net | 2,662,721 | | 1 | | 44,282 | | — | | — | | 44,283 | ||||||
| Vesting of restricted stock units | 9,913 | | — | | — | | — | | — | | — | ||||||
| Issuance of common stock upon exercise of stock options | | 338,987 | | | — | | | 986 | | | — | | | — | | | 986 |
| Issuance of common stock under ESPP | | 28,108 | | | — | | | 356 | | | — | | | — | | | 356 |
| Net loss | — | | — | | — | | — | | (75,521) | | (75,521) | ||||||
| Balance at December 31, 2023 | 27,762,703 | | $3 | | $272,640 | | $237 | | $(163,424) | | $109,456 | ||||||
| Unrealized loss on investments | — | | — | | — | | (132) | | — | | (132) | ||||||
| Issuance of common stock in connection with ATM, net | | 800,000 | | | — | | | 23,635 | | | — | | | — | | | 23,635 |
| Issuance of common stock upon exercise of stock options | | 382,790 | | | — | | | 1,484 | | | — | | | — | | | 1,484 |
| Issuance of common stock under ESPP | 34,034 | | — | | 308 | | — | | — | | 308 | ||||||
| Vesting of restricted stock units | 5,492 | | — | | — | | — | | — | | — | ||||||
| Stock based compensation | — | | — | | 11,311 | | — | | — | | 11,311 | ||||||
| Net loss | — | | — | | — | | — | | (69,628) | | (69,628) | ||||||
| Balance at December 31, 2024 | 28,985,019 | | $3 | | $309,378 | | $105 | | $(233,052) | | $76,434 | ||||||
| | | | | | | | | | | | | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.